Galmed Pharmaceuticals Ltd

NASDAQ:GLMD  
2.24
-0.19 (-7.82%)
Earnings Announcements

Galmed Pharma Provides Additional Positive Data From The Open Label Part Of ARMOR Study And Reports Q3 2021 Financial Results

Published: 11/08/2021 12:51 GMT
Galmed Pharmaceuticals Ltd (GLMD) - Galmed Pharmaceuticals Provides Additional Positive Data From the Open Label Part of Armor Study and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.31.
Qtrly Cash and Cash Equivalents $42.0 Million Versus $50.9 Million.
Q3 Earnings per Share View $-0.36 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.32

More details on our Analysts Page.